We recently compiled a list of 8 Cheap Growth Stocks to Buy According to Analysts. In this article, we will look at where ...
Zacks.com on MSN3d
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLCAstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung ...
We recently published a list of 10 Best Foreign Stocks To Buy Now. In this article, we are going to take a look at where ...
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
智通财经APP获悉，CDE网站显示，阿斯利康(AZN.US)的反义疗法Eplontersen(IONIS-TTR-LRx，商品名：Wainua)在华申报上市，用于治疗遗传性转甲状腺素介导的淀粉样变性多发性神经病(ATTRv-PN)。ATTRv-PN可 ...
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Check the time stamp on this data. Updated AI-Generated Signals for Astrazeneca Plc (AZN) available here: AZN.
05. 阿斯利康(AZN) 2023年收入超过450亿美元，拥有12种重磅药物，并在研发上投资了近110亿美元。公司的研发生产力为19%，高于行业平均水平14%，拥有超过120个处于第二和第三阶段的项目。阿斯利康的战略支柱包括科学与创新、生产力和增长、治疗领域的领导地位，以及人员和可持续性。公司设定了到2030年实现800亿美元收入的目标，并计划在2026年达到中30%的营业利润率。阿斯利康的资本 ...
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...
智通财经APP获悉，英国制药巨头阿斯利康(AZN.US)宣布，与第一三共株式会社共同研发的实验性抗癌药物达托泊单抗(Dato-DXD)在一项关键的乳腺癌治疗试验中未能延长患者生存期，与化疗相比没有显著优势。在这一消息的影响下，阿斯利康的股价在盘前交易中下跌了1.4%。公司表示，将与监管机构分享这些试验结果，并探讨是否应批准该药物上市。 这项研究针对的是那些无法手术切除或已经转移的激素受体阳性、HE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback